X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will support advancement of Mogrify’s dedicated pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Astellas Venture Management
Deal Size: $46.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 02, 2023
Details:
As part of the collaboration, Astellas Gene Therapies, is covering the research cost of the work as well as contributing its expertise in adeno-associated virus based genetic medicine and translational capabilities to complete experiments in pre-clinical models.
Lead Product(s): AAV-Based Genetic Medicine
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 05, 2022
Details:
Mogrify will discover and optimize cell conversion technology from iPSCs or ESCs to regulatory T cells. Sangamo will use Mogrify’s technology to create Tregs from iPSCs or ESCs.
Lead Product(s): CAR-Treg cell therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sangamo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
